Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Voice Technology to Identify Opioid Use

16 mai 2026 mis à jour par: Tenvos Inc.

Using Voice Technology to Identify Opioid Use in Patients in Treatment for Opioid Use Disorder

This study explored whether changes in a person's voice could help identify opioid use in patients with opioid use disorder (OUD). Current methods for determining whether a patient is intoxicated or in withdrawal often rely on self-reporting and clinical judgment, which can be subjective and inconsistent. Drug tests are logistically challenging to administer and can be costly with repeated use.

The project investigated whether physiological changes associated with opioid use could be detected through speech analysis technology. Researchers evaluated whether machine learning methods could identify voice patterns associated with opioid intoxication or withdrawal.

The primary goal of the study was to assess the accuracy of voice-based biomarkers in identifying opioid use. The study also explored relationships between opioid use and specific speech characteristics.

Aperçu de l'étude

Statut

Complété

Les conditions

Description détaillée

This study investigated whether changes in a person's voice could be used to identify opioid use in individuals with opioid use disorder (OUD). The opioid epidemic continues to present significant public health, medical, and social challenges in the United States and globally. Clinicians treating patients with OUD often need to determine whether a patient may be actively using opioids, intoxicated, withdrawing, or responding appropriately to treatment. Current approaches commonly rely on self-reporting, interviews, behavioral observations, urine toxicology testing, and clinical judgment. While these methods can be useful, they may also be subjective, resource-intensive, intermittent, invasive, or difficult to implement frequently in routine care settings.

The purpose of this project was to evaluate whether speech analysis technology could provide a more objective, scalable, and non-invasive approach for monitoring opioid-related physiological changes. Human speech is a complex neuromuscular activity that depends on the coordinated function of the brain, respiratory system, vocal tract, and facial musculature. Opioids can affect cognitive processing, respiratory patterns, motor coordination, reaction time, sedation levels, and muscle control, all of which may influence characteristics of speech production. Prior scientific literature has suggested that physiological and neurological conditions can sometimes produce measurable changes in speech patterns. This project sought to determine whether similar measurable changes could be associated with opioid use.

The study focused specifically on analyzing speech recordings from participants with opioid use disorder. Researchers collected voice samples and applied computational analysis methods to evaluate whether acoustic and temporal speech features could distinguish opioid-related states. The project used signal-processing techniques and machine learning methods to analyze a range of speech characteristics that may reflect physiological effects associated with opioid exposure.

Evaluated speech features included acoustic biomarkers commonly studied in speech analytics research. The project investigated whether combinations of these features could be used to identify patterns associated with opioid intoxication or withdrawal.

A major goal of the study was to assess the feasibility of using speech as a physiological biomarker for opioid use monitoring. Researchers evaluated whether machine learning models could reliably differentiate between opioid-related conditions using speech data alone.

The primary objective of the study was to assess the accuracy and feasibility of voice-based biomarkers for identifying opioid use in individuals with OUD. The study also aimed to better understand the limitations and challenges associated with speech-based impairment detection.

As part of the research effort, the project contributed to the development of internal workflows and analytic infrastructure for handling sensitive speech data. Researchers established preprocessing pipelines for audio ingestion, normalization, feature extraction, labeling, quality control, and model evaluation.

The work generated technical findings regarding the feasibility of speech-based opioid detection and highlighted several scientific and engineering challenges associated with this problem space. These included variability in recording environments, differences between speakers, background noise, individual physiological differences, and the difficulty of isolating opioid-related speech effects from unrelated sources of variation. The study also reinforced the challenges associated with developing generalized machine learning classifiers for complex real-world physiological states using speech data alone.

Although the project explored the potential for objective opioid monitoring through speech analysis, the research did not produce a clinically deployable classifier during the study period. However, the project generated valuable information regarding the limitations, feasibility considerations, and technical barriers associated with speech-based opioid detection approaches. These findings informed future research planning, technology-development decisions, and evaluation strategies for impairment-detection technologies.

Overall, the project contributed to ongoing research efforts exploring non-invasive digital biomarkers for substance-use monitoring. The findings from this work may help guide future investigations into speech analytics, physiological monitoring, and machine learning approaches for identifying substance-related impairment and supporting clinical decision-making in addiction medicine settings.

Type d'étude

Observationnel

Inscription (Réel)

41

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • California
      • Loma Linda, California, États-Unis, 92350
        • Loma Linda University Health, 24951 Circle Drive, Nichol Hall, Room #2042

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

The study population is adult (18+) English-speaking men and women currently receiving OUD treatment at the Volpicelli Center, capable of consenting and completing the protocol, and free of severe psychiatric comorbidity or chronic speech-affecting conditions. Because participants are drawn from an active treatment population, they are by definition individuals already engaged in care for OUD rather than treatment-naïve or general-population samples - a relevant consideration when interpreting how the voice biomarker findings might generalize.

La description

Inclusion Criteria:

  • Male or female
  • At least 18 years old
  • Be an active patient in treatment at the Volpicelli Center
  • Have a diagnosis of Opioid Use Disorder (OUD)
  • Ability to read English
  • Able to comprehend and are willing to sign the informed consent form and are able to adhere to the protocol

Exclusion Criteria:

  • Severe psychiatric comorbidity
  • A chronic medical condition that interferes with speaking (note: Acute conditions that impair speech or hearing will not be considered exclusionary, but testing will be deferred until the temporary condition has been resolved)
  • Non-fluency in the study language (English)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Patients in treatment for opioid use disorder at the Volpicelli Center.
Prospective longitudinal observational cohort study with repeated measures where each participant completed two visits approximately 30 days apart with repeated speech and clinical measurements. This is a prospective observational study therefore no intervention will be applied.
Not Applicable - Observational Study

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Sensitivity and Specificity
Délai: 12 months after the enrollment
Sensitivity and Specificity of the machine learning model when classifying voice samples into patient's state based on their speech.
12 months after the enrollment

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
List of specific voice features/categories affected by substances
Délai: 12 months after enrollment
Identify voice features/categories most affected by the following substances: Buprenorphine, Other Opioid, Opioid Antagonist, Stimulant, Sedative, Cannabinoid.
12 months after enrollment

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

10 décembre 2024

Achèvement primaire (Réel)

30 juin 2025

Achèvement de l'étude (Réel)

30 janvier 2026

Dates d'inscription aux études

Première soumission

10 mai 2026

Première soumission répondant aux critères de contrôle qualité

16 mai 2026

Première publication (Réel)

22 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

22 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 mai 2026

Dernière vérification

1 mai 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 0612
  • 1R43DA060696-01 (Subvention/contrat des NIH des États-Unis)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner